What drove ALDEI.PA stock activity today?

High liquidity drove activity: **13,014,939** shares traded, about **2.17x** average. Volume growth often reflects speculative flows, news scanning, or technical trading in microcap biotech names.

What is Meyka AI’s grade and what does it mean for ALDEI.PA stock?

Meyka AI rates ALDEI.PA **61.03/100 (B, HOLD)**. The grade balances sector and benchmark comparisons with financial metrics and forecasts to indicate cautious monitoring rather than a clear buy signal.

What price target does Meyka AI forecast for ALDEI.PA stock?

Meyka AI’s forecast model projects a 12-month base target of **€0.0450**, implying **+69.81%** from current **€0.0265**. Forecasts are model-based projections and not guarantees.

How risky is investing in ALDEI.PA stock?

ALDEI.PA stock is high risk due to negative earnings, small market cap (**€1.13M**), and milestone-driven valuation. It is suitable for speculative portfolios or as a monitored position rather than core holdings.

EU Stocks

€0.03 close for Deinove SA (ALDEI.PA, EURONEXT) 29 Jan 2026: high volume insight

ByDanny Kontos January 30, 2026January 30, 2026

ALDEI.PA stock closed the EURONEXT session on 29 Jan 2026 at €0.0265, with 13,014,939 shares traded, making it one of the most active small-caps on Europe’s exchange today. Volume was 2.17x the average, pushing the price to a intraday high of €0.0321 and a low of €0.0231. Traders focused on liquidity and speculative flows, while fundamentals show a biotech firm still funding R&D with negative EPS of -0.24. We review trading drivers, financials, sector context and Meyka AI’s grade and forecast for ALDEI.PA stock.